Catalog No. size 价格库存数量
S5809-2 2mg solid ¥276
售罄
不可用
S5809-10 10mg solid ¥1,116
售罄
不可用

详情描述

VTX-27 is a novel potent and selective PKCθ inhibitor.

Product information

CAS Number: 1321924-70-2

Molecular Weight: 418.90

Formula: C20H24ClFN6O

Synonym:

VTX 27

VTX27

Chemical Name: (2R)-2-[(2S)-4-[3-Chloro-5-fluoro-6-(2H-pyrazolo[3, 4-b]pyridin-3-yl)pyridin-2-yl]piperazin-2-yl]-3-methylbutan-2-ol

Smiles: CC(C)[C@@](C)(O)[C@@H]1CN(CCN1)C1=NC(=C(F)C=C1Cl)C1NN=C2N=CC=CC2=1

InChiKey: HXWARSZQGAFXJM-MGPUTAFESA-N

InChi: InChI=1S/C20H24ClFN6O/c1-11(2)20(3,29)15-10-28(8-7-23-15)19-13(21)9-14(22)17(25-19)16-12-5-4-6-24-18(12)27-26-16/h4-6,9,11,15,23,29H,7-8,10H2,1-3H3,(H,24,26,27)/t15-,20+/m0/s1

Technical Data

Appearance: Solid Power.

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: Soluble in DMSO

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: 0 - 4 oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined.

HS Tariff Code: 382200

How to use

In Vitro:

VTX-27 (Compound 27) possesses excellent overall characteristics. Good selectivity of VTX-27 is also seen against other PKC family members, particularly classical isoforms (>1000-fold except PKCβ I, 200-fold) and atypical isoforms (>10000-fold). As anticipated, attaining selectivity over the more closely related novel PKC family members is more challenging, with a good 200-fold being achieved over PKC δ.

In Vivo:

VTX-27 shows the best PK profile with a low clearance (7 mL min-1 kg-1), long half-life (4.7 h), and good oral bioavailability (65%). A single dose of VTX-27 is administered orally at 6.25, 12.5, 25, and 50 mg/kg (e.g., at 25 mg/kg Cmax concentration 700 ng/mL) and demonstrates potent dose dependent inhibition of IL-2 production

References:

  1. Jimenez JM, et al. Design and optimization of selective protein kinase C θ (PKCθ) inhibitors for the treatment of autoimmune diseases. J Med Chem. 2013 Mar 14;56(5):1799-810.

Products are for research use only. Not for human use.

相似产品

Recently viewed